SATSUMA PHARMACEUTICALS INC's ticker is STSA and the CUSIP is 80405P107. A total of 33 filers reported holding SATSUMA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $289,419 | +78546.5% | 414,344 | +1.3% | 0.00% | – |
| Q4 2022 | $368 | -100.0% | 409,108 | +113.7% | 0.00% | – |
| Q3 2022 | $1,148,000 | +68.3% | 191,445 | +16.2% | 0.00% | – |
| Q2 2022 | $682,000 | +68.8% | 164,738 | +54.9% | 0.00% | – |
| Q1 2022 | $404,000 | -14.8% | 106,370 | +0.8% | 0.00% | – |
| Q4 2021 | $474,000 | +3.0% | 105,486 | +6.8% | 0.00% | – |
| Q3 2021 | $460,000 | -11.0% | 98,803 | +34.6% | 0.00% | – |
| Q2 2021 | $517,000 | -26.8% | 73,400 | -38.6% | 0.00% | – |
| Q1 2021 | $706,000 | +52.8% | 119,557 | +19.1% | 0.00% | – |
| Q4 2020 | $462,000 | +4.1% | 100,355 | -12.2% | 0.00% | – |
| Q3 2020 | $444,000 | -86.7% | 114,328 | -1.2% | 0.00% | -100.0% |
| Q2 2020 | $3,327,000 | +88.8% | 115,702 | +41.3% | 0.00% | – |
| Q1 2020 | $1,762,000 | -30.6% | 81,892 | -36.5% | 0.00% | – |
| Q4 2019 | $2,538,000 | – | 129,006 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 3,711,286 | $22,268,000 | 3.58% |
| NEA Management Company, LLC | 3,142,958 | $18,858,000 | 0.94% |
| Vivo Capital, LLC | 1,232,394 | $7,394,000 | 0.82% |
| RA Capital Management | 5,914,252 | $35,486,000 | 0.76% |
| Nan Fung Group Holdings Ltd | 177,900 | $1,067,000 | 0.68% |
| Ikarian Capital, LLC | 400,000 | $2,400,000 | 0.48% |
| SAMLYN CAPITAL, LLC | 2,929,195 | $17,575,000 | 0.33% |
| EAM Investors, LLC | 149,029 | $894,000 | 0.19% |
| TPG GP A, LLC | 1,885,939 | $11,316,000 | 0.18% |
| Ikarian Capital, LLC | 136,059 | $815,000 | 0.16% |